Neogenomics (NEO) Common Equity (2010 - 2026)

Neogenomics (NEO) has 17 years of Common Equity data on file, last reported at $785.7 million in Q2 2026.

• Quarterly Common Equity fell 8.0% year-over-year to $785.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $785.7 million (down 8.0% YoY) and the FY2025 annual result came in at $836.6 million, down 7.29% from the prior year.
• Common Equity slipped to $785.7 million in Q2 2026, from $828.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.1 billion in Q1 2022 to a low of $785.7 million in Q2 2026.
• A 5-year average of $923.9 million and a median of $919.6 million in 2024 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 27.41% in 2022, down 10.93% in 2022.
• Tracing NEO's Common Equity over 5 years: stood at $998.0 million in 2022, then decreased by 5.66% to $941.5 million in 2023, then declined by 4.16% to $902.3 million in 2024, then dropped by 7.29% to $836.6 million in 2025, then dropped by 6.08% to $785.7 million in 2026.
• The last three Common Equity figures came in at $785.7 million (Q2 2026), $828.8 million (Q1 2026), and $836.6 million (Q4 2025), per Business Quant data.